In this analysis of the phase 3 ALLTO trial, researchers explored 10-year outcomes of HR+, HER2+ early breast cancer patients who received either an aromatase inhibitor or a selective estrogen ...
Phase 1b study to evaluate combination of zongertinib and zanidatamab in HER2-positive breast cancer patients Ingelheim, Germany– 12 January, ...
Enhertu plus Perjeta improved median PFS to 40.7 months versus 26.9 months with standard care in HER2-positive breast cancer. The PFS benefit was consistent across subgroups, including hormone ...
HER2-positive cancers overexpress the human epidermal growth factor receptor 2. When expressed at abnormally high levels, HER2 leads to uncontrolled cell growth and a more aggressive behavior than ...
New York, New York--(Newsfile Corp. - August 7, 2025) - OS Therapies (OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical ...
Enhertu plus Perjeta showed superior PFS compared to THP in HER2-positive advanced/metastatic breast cancer, irrespective of prior treatment, hormone receptor status, or PIK3CA mutations. Enhertu plus ...
(RTTNews) - Radiopharm Theranostics Limited (RADX), on Monday announced promising new data from the European Molecular Imaging Meeting or EMIM 2025, showcasing the potential of 68Ga-RAD202 for imaging ...
– The Itovebi (inavolisib)-based regimen reduced the risk of death by more than 30% in people with PIK3CA-mutated HR-positive, HER2-negative advanced breast cancer, compared with palbociclib and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback